Jazz Pharma (JAZZ) EPS Miss Overshadowed By Settlements - UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Mizuho Securities Upgrades Jazz Pharmaceuticals (JAZZ) to Buy on Xyrem Settlements
May 11, 2016 6:17 AM EDTMizuho Securities upgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Neutral to Buy with a price target of $193.00 (from $137.00) on Xyrem Settlements.
Analyst Irina Koffler commented, "Jazz's announcement of its late 2025 Xyrem settlements was the upgrade signal we were looking for. We modeled Xyrem... More
Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 5c; Guides In-Line
May 10, 2016 4:08 PM EDTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $2.26, $0.05 worse than the analyst estimate of $2.31. Revenue for the quarter came in at $336 million versus the consensus estimate of $338.86 million.
"During the first quarter of 2016, we executed on our business model by delivering strong top-... More
